An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease

NCT00071877 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

NIH

Sponsor class

Conditions

Fabry Disease

Interventions

DRUG: Replagal

Sponsor

National Institute of Neurological Disorders and Stroke (NINDS)